Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma.

Reena P ThomasSeema NagpalMichael IvScott G SoltysSophie BertrandJudith S PelpolaRobyn BallJaden YangVandana SundaramJonathan LavezoDonald BornHannes VogelJ Martin BrownLawrence D Recht

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Infusion of the CXCR4 inhibitor plerixafor was well tolerated as an adjunct to standard chemoirradiation in patients with newly diagnosed GBM and improves local control of tumor recurrences.

Keyphrases

newly diagnosed
radiation therapy
endothelial cells
cell migration
study protocol
low dose
clinical trial
adipose tissue
phase iii
induced pluripotent stem cells
phase ii
locally advanced
open label